Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal CancerJun Watanabe, Takayuki Yoshino, Kei Muro et al.|JAMA|2023Cited by 255
Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancerHisatsugu Ohori, Hiroyuki Shibata, Yoshiharu Iwabuchi et al.|Molecular Cancer Therapeutics|2006Cited by 243
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerKohei Shitara, Takayuki Yoshino, Kei Muro et al.|Nature Medicine|2024Cited by 108
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.Takayuki Yoshino, Kei Muro, Jun Watanabe et al.|Journal of Clinical Oncology|2022Cited by 69
Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.Kohei Shitara, Takayuki Yoshino, Kei Muro et al.|Journal of Clinical Oncology|2023Cited by 35